RSV Season and Synagis Prior Authorization Ends On Schedule for All Health Service Regions

Date: March 24, 2026

Attention: Providers

Call to action: Vendor Drug Program (VDP) will end the 2025-26 respiratory syncytial virus season for all health service regions as scheduled. MCOs like Texas Children’s will no longer accept or review Synagis prior authorization requests once the region has closed. 2025-26 RSV Season Schedule

Background: Human Respiratory Syncytial Virus (RSV) causes respiratory tract infections and severe lung disease in infants and children. Synagis (palivizumab) is available for children with a high risk of infection.

How this impacts providers: Respiratory Syncytial Virus Treatment

Next step for Providers: Providers should share this information with the staff.

If you have any questions, please email Provider Relations at providerrelations@texaschildrens.org. 

For access to all provider alerts www.texaschildrenshealthplan.org/provideralerts.